Diabetes caused by Kir6.2 mutation: Successful treatment with oral glibenclamide switched from continuous subcutaneous insulin infusion in the early phase of the disease

Pediatrics International

Volumn 54, Issue 2, 2012, Pages 277-279

  Nagano, Nobuhiko ^a   Urakami, Tatsuhiko ^a   Mine, Yusuke ^a   Watanabe, Hirofumi ^a   Yoshida, Ayako ^a   Suzuki, Junichi ^a   Saito, Hiroshi ^a   Ishige, Mika ^a   Takahashi, Shori ^a   Mugishima, Hideo ^a   Yorifuji, Tohru ^b  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

early infancy; KCNJ11 mutation; neonatal diabetes; sulfonylurea treatment

Indexed keywords

BICARBONATE; C PEPTIDE; GLIBENCLAMIDE; GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; HEMOGLOBIN F; INSULIN; INSULIN LISPRO; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2;

AMINO ACID SUBSTITUTION; ARTICLE; BLOOD PH; CASE REPORT; CONTINUOUS INFUSION; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE MUTATION; GENETIC ANALYSIS; GESTATIONAL AGE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INFANT; INSULIN INFUSION; KETOACIDOSIS; MALE; NEWBORN DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT RESPONSE; URINALYSIS;

ADMINISTRATION, ORAL; DIABETES MELLITUS; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INFANT, NEWBORN; INFUSIONS, SUBCUTANEOUS; INSULIN; MALE; POTASSIUM CHANNELS, INWARDLY RECTIFYING;

EID: 84859906039     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2011.03413.x     Document Type: Article

References (10)

1. Sperling MA,. ATP-sensitive potassium channels: Neonatal diabetes mellitus and beyond. N. Engl. J. Med. 2006; 355: 507-10.
2. Sagen JV, Raeder H, Hathout E, et al,. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: Patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004; 53: 2713-18.
3. Ewan RP, Flechtner I, Pal RN, et al,. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N. Engl. J. Med. 2006; 355: 467-77.
4. Codner E, Flanagan SE, Ugarte F, et al,. Sulfonylurea treatment in young children with neonatal diabetes. Diabetes Care 2007; 30: 28-9.
5. Edghill EL, Hattersley AT,. Genetic disorders of the pancreatic beta cell and diabetes (permanent neonatal diabetes and maturity-onset diabetes of the young). In:, Seino S, Bell GI, (eds). Pancreatic Beta Cell in Health and Disease. 1. Springer, Japan, 2008; 389-420.
6. Edghill EL, Flanagan SE, Patch AM, et al,. Insulin mutation screening in 1044 patients with diabetes: Mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes 2008; 57: 1034-42.
7. Flanagan SE, Patch AM, Mackay DJ, et al,. Mutations in ATP-sensitive K+ channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes 2007; 56: 1930-37.
8. Ito Y, Matsuo S, Matsuo Y, et al,. A therapeutic approach in a patient with neonatal diabetes. Clin. Pediatr. Endocrinol. 2001; 10: 125-9.
9. Loomba-Albrecht LA, Glaser NS, Styne DM, et al,. An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus. Clin. Ther. 2009; 31: 816-20.
10. Gloyn AL, Pearson ER, Antcliff JF, et al,. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med. 2004; 350: 1838-49.